BioTuesdays

Category - Markets

Neuronetics Logo
Markets

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

October 13, 2021
Dice-Therapeutics
Markets

SVB Leerink starts DICE Therapeutics at OP; PT $46

SVB Leerink launched coverage of Dice Therapeutics (NASDAQ:DICE) with an “outperform” rating and $46 price target. The stock closed at $26.49 on Oct. 8. DICE is a biopharmaceutical company leveraging its proprietary...

October 11, 2021
Markets

HCW starts Vyant Bio at buy; PT $5

H.C. Wainwright initiated coverage of Vyant Bio (NASDAQ:VYNT) with a “buy” rating and price target of $5. The stock closed at $2.21 on Oct. 5. Vyant is a biotechnology company focused on identifying therapeutic drugs...

October 6, 2021
RenovoRX
Markets

Maxim starts RenovoRx at buy; PT $15

Maxim Group launched coverage of RenovoRx (NASDAQ:RNXT) with a “buy” rating and price target of $15. The stock closed at $5.72 on Oct.5. RenovoRx is developing a therapeutic platform known as, RenovoTAMP (Trans-Arterial...

October 6, 2021
Affimed
Markets

Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

September 30, 2021
Clarus-Therapeutics
Markets

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

September 29, 2021
Markets

Stifel starts Repare Therapeutics at buy; PT $48

Stifel launched coverage of Repare Therapeutics (NASDAQ:RPTX) with a “buy” rating and $48 price target. The stock finished at $28.48 on Sept. 22. Analyst Benjamin Burnett, Ph.D., writes that his rating is largely...

September 23, 2021